Pharmaceutical firm Cipla on Friday said the US Food and Drug Administration has completed inspection of its Bengaluru-based manufacturing unit with four observations.
The company said it is committed to addressing these observations and will submit its response to the USFDA within the stipulated time.
The inspection of Cipla's API manufacturing facility was carried out between January 20 and 24.
"The United States Food and Drug Administration conducted a cGMP inspection at our API manufacturing facility in Bommasandra, Bangalore, from January 20, 2020, to January 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity," Cipla said in a stock exchange filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app